The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking
Authors' conclusion
MetS aggravated the damage of LV deformation and function in OCAD patients and was independently associated with LV deformation and impaired LV strain. Additionally, MetS increased the prediction efficiency of increased LVM and decreased LV GLPS. Early detection and intervention of MetS in patients with OCAD is of great significance.
Study context
- Population
- Patients with obstructive coronary artery disease who underwent cardiac MRI, and sex- and age-matched controls121 obstructive coronary artery disease (OCAD) patients
- Participants
- 83 / 38 / 52
- Exposure
- OCAD with metabolic syndrome (MetS) vs OCAD without MetS vs controls
- OCAD(MetS+)n = 83
- OCAD(MetS-)n = 38
- Controlsn = 52reference
- Outcome
- LV mass, LV global function index and LV global longitudinal peak strain
Methodological detailscardiac magnetic resonance feature tracking, sex- and age-matched controls
- Cardiac magnetic resonance feature tracking
- Sex- and age-matched controls
Main finding
As reported in the abstract
- From controls to OCAD(MetS-) to OCAD(MetS+), LV mass (LVM) increased and LV global function index (LVGFI) and left ventricular (LV) global longitudinal peak strain (GLPS) decreased
- all p < 0.05
Observational data: associations, not effects.
Further findings
MetS as independent factor of LV impairment in OCAD (adjusted multivariable linear regression)
- MetS and decreased LV GLPS, β
- - 0.211, p = 0.002
- MetS and increased LVM, β
- 0.221, p = 0.003
- Adjusted for covariates
Prediction of LV impairment with combined MetS (logistic regression and ROC)
- AUC for LV GLPS reduction
- 0.88
- AUC for LVM increase
- 0.89
Original publication
The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking. Cardiovasc Diabetol. Published 23 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →